LONDON, Jan 26 (Reuters) - The EU drug regulator on Friday did not mention Novo Nordisk's popular weight-loss drug Wegovy in notes and recommendations it published following a meeting of a committee which reviews drugs for use in the region.

On Monday, the European Medicines Agency (EMA) said its Committee for Medicinal Products for Human Use (CHMP) would review Wegovy this week for possible wider use to include reducing the risk of strokes and heart attacks.

The results of the meeting were released on Friday afternoon. (Writing by Josephine Mason; editing by Jason Neely)